CXCL14 and head and neck squamous cell carcinoma: The upregulation of MHC-I expression and the presentation of epitopes from the HPV vaccines could also enhance the efficacy of ICI therapy, establishing CXCL14 as an immunotherapeutic agent for effective strategies to treat HPV+ HNSCC.